ÂÜÀòÂÒÂ×

Jeff Wiezorek, MD, is co-founder and CMO. He was previously senior vice president of development at Kite and led development of all CAR and TCR-engineered T cell programs including the first CAR-T therapy approved for non-Hodgkin Lymphoma. Before that, Jeff held roles of increasing responsibility over nine years at Amgen including oversight of the development teams for BLINCYTO, IMLYGIC, XGEVA, Vectibix, as well as leading the immunotherapy, angiogenesis, and bone oncology product areas encompassing Phase 1-4 clinical trials. Jeff trained in internal medicine at Stanford University and completed a fellowship in oncology at the UCLA, and did postdoctoral research with Dr. David Baltimore at Caltech. Jeff received his MD from Columbia University and a BA in biophysics from the University of Pennsylvania.